Treatment of elderly patients with chronic lymphocytic leukemia

References

• Ries L AG, Melbert D, Krapcho M, Stinchcomb D G, Howlader N, Horner M J, et al. SEER Clinical Statistics Review, 1975–2005. National Cancer Institute, Bethesda, MD 2008
   Google Scholar
• Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325
   PubMed Web of Science ®Google Scholar
• Eichhorst B F, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, Oscier D, Dyer M J, Bezares R F, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239
   PubMed Web of Science ®Google Scholar
• Flinn I W, Neuberg D S, Grever M R, Dewald G W, Bennett J M, Paietta E M, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007; 25: 793–798
   PubMed Web of Science ®Google Scholar
• Byrd J C, Peterson B L, Morrison V A, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14
   PubMed Web of Science ®Google Scholar
• Keating M J, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–4088
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078
   PubMed Web of Science ®Google Scholar
• Wierda W G, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do K A, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109: 4679–4685
   PubMed Web of Science ®Google Scholar
• Goede V, Cramer P, Busch R, Eichhorst B H, Hallek M, GCLLSG. Distribution and impact of comorbidity in chronic lymphocytic leukemia: meta-analysis of two phase III trials of the German CLL Study Group (GCLLSG). Leuk Lymphoma 2005; 46: 105
   Google Scholar
• Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008; 49: 49–56
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Grever M R, Lucas D M, Dewald G W, Neuberg D S, Reed J C, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799–804
   PubMed Web of Science ®Google Scholar
• Josefsson P, Geisler C H, Leffers H, Petersen J H, Andersen M K, Jurlander J, Buhl A M. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007; 109: 4973–4979
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Wen S, O'Brien S, McLaughlin P, Wierda W G, Ferrajoli A, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007; 25: 4648–4656
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do K A, et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006; 106: 337–345
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James M R, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89: 2516–2522
   PubMed Web of Science ®Google Scholar
• Piccirillo J F, Tierney R M, Costas I, Grove L, Spitznagel E L, Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441–2447
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen M L, van Spronsen D J, Lemmens V E, Houterman S, Verheij K D, Coebergh J W. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International prognostic index. Br J Haematol 2005; 129: 597–606
   PubMed Web of Science ®Google Scholar
• Cramer P, Goede V, Jenke P, Busch R, Hallek M, Eichhorst B. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III-trials of the German CLL study group. Blood 2006; 108
   Google Scholar
• Extermann M, Overcash J, Lyman G H, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582–1587
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson B D, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008; 111: 5446–5456
   PubMed Web of Science ®Google Scholar
• Eichhorst B F, Busch R, Stauch M, Bergmann M, Ritgen M, Kranzhöfer N, et al. No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a phase III study of the German CLL study group (GCLLSG). Blood 2007; 110
   Google Scholar
• Forconi F, Fabbri A, Lenoci M, Sozzi E, Gozzetti A, Tassi M, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008; 26: 247–251
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O'Brien S, Wierda W, Lerner S, Faderl S, Kantarjian H, Keating M. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma 2005; 46: 48
   Google Scholar
• Shanafelt T D, Lin T, Geyer S M, Zent C S, Leung N, Kabat B, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109: 2291–2298
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O'Brien S, Faderl S, Wierda W, Jorgensen J, Keating M J. The combination of rituximab and GM-CSF as frontline treatment for elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2007; 48(Suppl 1)5.03
   Google Scholar
• Robertson L E, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 1444–1449
   PubMed Web of Science ®Google Scholar
• Shvidel L, Shtalrid M, Bairey O, Rahimi-Levene N, Lugassy G, Shpilberg O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 1947–1950
   PubMed Web of Science ®Google Scholar
• Fabbri A, Lenoci M, Gozzetti A, Marotta G, Raspadori D, Forconi F, Lauria F. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J 2004; 5: 472–474
   PubMedGoogle Scholar
• Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268–1270
   PubMed Web of Science ®Google Scholar
• Bezares R F, Murro H H, Celebrin L, Caviglia D, Lafalce D, Alcorta S. Fludarabine (F) administered on a three (F3a) alternate day-basis in selected CLL patients. Leuk Lymphoma 2001; 42: 53
   Google Scholar
• Wright J R, Ung Y C, Julian J A, Pritchard K I, Whelan T J, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027–1032
   PubMed Web of Science ®Google Scholar
• Smith R E, Jr, Aapro M S, Ludwig H, Pintér T, Smakal M, Ciuleanu T E, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1040–1050
   PubMed Web of Science ®Google Scholar
• Aapro M, Scherhag A, Burger H U. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008; 99: 14–22
   PubMed Web of Science ®Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97: 489–498
   PubMed Web of Science ®Google Scholar
• Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Cheson B D, Frame J N, Vena D, Quashu N, Sorensen J M. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 2313–2320
   PubMed Web of Science ®Google Scholar
• Bosly A, Sonet A, Pinkerton C R, McCowage G, Bron D, Sanz M A, Van den Berg H. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003; 98: 1048–1054
   PubMed Web of Science ®Google Scholar
• Eichhorst B F, Busch R, Schweighofer C, Wendtner C M, Emmerich B, Hallek M. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 2007; 136: 63–72
   PubMed Web of Science ®Google Scholar
• Thome B, Hallberg I R. Quality of life in older people with cancer – a gender perspective. Eur J Cancer Care (Engl) 2004; 13: 454–463
   PubMed Web of Science ®Google Scholar
• Wedding U, Rohrig B, Pientka L, Hoffken K. Anaemia-related impairment in quality of life in elderly cancer patients prior to chemotherapy. J Cancer Res Clin Oncol 2007; 133: 279–286
   PubMed Web of Science ®Google Scholar
• Prause W, Saletu B, Tribl G G, Rieder A, Rosenberger A, Bolitschek J, et al. Effects of socio-demographic variables on health-related quality of life determined by the quality of life index – German version. Hum Psychopharmacol 2005; 20: 359–365
   PubMed Web of Science ®Google Scholar